Conference Menu

Register 
Overview
Day 1
Day 2
Short Courses
Breakout Discussions
Hotel & Travel
Posters
PDF Download
Sponsor & Exhibits 
Press Pass
Request Brochure  
Archives 


Corporate Sponsor 

Codexis


Lead Sponsoring Publications 

Science AAAS 

The Scientist 


Sponsoring Publications

PharmaVoice 

 Genome Technology 

Open Process Chemistry Journal 


Media Partners

Bentham Science 

GenomeWeb 


 

Pharmcast 


 


Breakout Discussions


Conference Proceeding CD Now Available
  • Speaker Presentations
  • Poster Abstracts
  • and More!

Roundtable Breakout Discussions 

June 13, 4:05 PM


ROUNDTABLE BREAKOUT DISCUSSIONS

In this interactive session, audience members choose one of the breakout topics listed below and join the moderated discussion at hand. Participants are encouraged to share examples from their work, vet ideas with peers and ask questions of one another. This discussion is a relaxed, informal exchange amongst scientists and is not meant to be, in any way, a corporate or specific product discussion.

Topic: Process Control Justifications

Co-Moderators: Matthew Ravn, Ph.D., Senior Scientist III, GPRD Process R&D, Abbott

Robert Hughes, Ph.D., Chemical Development, Vertex Pharmaceuticals Inc.

  • Success or failures in experimental models – pathway to file and do they provide regulatory flexibility?
  • How does interpretation of QbD impact execution of Process Control Justficiations (PCJ)?
  • PCJ experimental approaches - forward (process), backward (risk assessment) or somewhere in between?
  • Success or failures on incorporation of PAT into PCJ and process validation.

Topic: Impurities and the Regulatory Environment

Moderator: Michelle Kenyon, DSRD, Genetic Toxicology, Pfizer Global Research and Development

  • What type of impurity information (safety/quality) is being disclosed in regulatory submissions?
  • How do we deal with differing regulatory views regarding impurities for global submissions?
  • Are compound-specific PDEs being used/accepted to justify levels of impurities above the TTC?
  • How is ICH S9 being applied for oncology products and is it generally accepted by regulators?

Topic: Control of Final Form

Moderator: Neal Anderson, Ph.D., President, Anderson’s Process Solutions

  • Advanced technologies for detecting crystal polymorphs
  • How much of a crystal polymorph is too much?
  • What are the most relevant critical quality attributes?
  • What/when to report about crystal polymorphs
 

Add to Outlook


By Series:
By Region:


Conference
& Course Catalog

CHI Catalog 


Short Course DVDs